22
Views
39
CrossRef citations to date
0
Altmetric
Research Article

Interaction of Anticancer Drugs with Hepatic Monooxygenase Enzymes

&
Pages 395-439 | Published online: 22 Sep 2008

References

  • Metabolism and action of anti-cancer drugs, G. Powis, R. A. Prough. Taylor & Francis, London 1987; 1–336
  • Carter S. K., Livingston R. B. Principles of cancer chemotherapy. Principles of Cancer Treatment, S. K. Carter, E. Blatstein, R. B. Livingston. McGraw-Hill, New York 1982; 95–110
  • Wislocki P. G., Miwa G. T., Lu A. Y. H. Reactions catalysed by the cytochrome P-450 system. Enzymatic Basis of Detoxification, W. B. Jakoby. Academic Press, New York 1980; vol. 1: 135–182
  • Gelboin H. V. Benzo[a]pyrene metabolism, activation, and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes. Physiol. Rev. 1980; 60: 1107–1166
  • Conney A. H. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes memorial lecture. Cancer Res. 1982; 42: 4875–4917
  • Coon M. J., Koop D. R. P-450 oxygenases in lipid transformation. Enzymes 1983; 16: 645–677
  • Nebert D. W., Nelson D. R., Adesnik M., Coon M. J., et al. The P450 superfamily: Updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA 1989; 8: 1–13
  • Waxman D. J. Rat hepatic cytochrome P-450: comparative studies of multiple isozymic forms. Cytochrome P-450: Structure, Mechanism and Biochemistry, P. R. Ortiz de Montellano. Plenum Press, New York 1986; 525–539
  • Waxman D. J. Interactions of hepatic cytochromes P-450 with steroid hormones. Regioselectivity and stereospecificity of steroid hydroxylation and hormonal regulation of rat P-450 enzyme expression. Biochem. Pharmacol. 1988; 37: 71–84
  • Schwab G. E., Johnson E. F. Enzymology of rabbit cytochromes P-450. Mammalian Cytochromes P-450, F. P. Guengerich. CRC Press, Boca Raton, FL 1987; vol. 1: 55–105
  • Distlerath L. M., Guengerich F. P. Enzymology of human liver cytochromes P-450. Mammalian Cytochromes P-450, F. P. Guengerich. CRC Press, Boca Raton, FL 1987; vol. 1: 134–198
  • Guengerich F. P. Enzymology of rat liver P-450 cytochromes. Mammalian Cytochromes P-450. CRC Press, Boca Raton, FL 1987; vol. 1: 1–54
  • Cytochrome P-450. Structure, mechanism, and biochemistry, P. R. Ortiz de Montellano. Plenum Press, New York 1986; 1–556
  • Adesnik M., Atchison M. Genes for cytochrome P-450 and their regulation. Critical Rev. Biochem. 1985; 19: 247–305
  • Ortiz de Montellano P. R., Reich N. O. Inhibition of cytochrome P-450 enzymes, Cytochrome P-450. Structure Mechanism and Biochemistry, P. R. Ortiz de Montellano. Plenum Press, New York 1986; 273–314
  • Whitlock J. P., Jr. The regulation of cytochrome P-450 gene expression. Ann. Rev. Pharmacol. Toxicol. 1986; 26: 333–369
  • Friedman O. M., Myles A., Colvin M. Cyclophosphamide and phosphoramide mustards. Adv. Cancer Chemother. 1979; 1: 143–204
  • Cohen J. L., Jao J. Y. Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat. J. Pharmacol. Exp. Ther. 1970; 174: 206–210
  • Cox P. J., Farmer P. B., Jarman M. Metabolism and mechanism of action of cyclophosphamide. Cancer Treat. Rep. 1976; 60: 299–525
  • Gurtoo H. L., Marinello A. J., Struck R. F., Paul B., Dahms R. P. Studies on the mechanism of denaturation of cytochrome P-450 by cyclophosphamide and its metabolites. J. Biol. Chem. 1981; 256: 11691–11701
  • Colvin M., Hilton J. Pharmacology of cyclophosphamide and metabolites. Cancer Treat. Rep. 1981; 65(suppl. 3)89–95
  • Sladek N. E. Oxazaphosphorines. Metabolism and Action of Anticancer Drugs, G. Powis, R. A. Prough. Taylor & Francis, New York 1987; 48–90
  • Sladek N. E. Therapeutic efficacy of cyclophosphamide as a function of its metabolism. Cancer Res. 1972; 32: 535–542
  • Jao J. Y., Jusko W. J., Cohen J. L. Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res. 1972; 32: 2761–2764
  • Struck R. F., Kari P., Kalin J., Montgomery J. A., Marinello A. J., Love J., Bansal S. K., Gurtoo H. L. Metabolism of cyclophosphamide by purified cytochrome P-450 from microsomes of phenobarbital-treated rats. Biochem. Biophys. Res. Commun. 1984; 120: 390–396
  • Clarke L., Waxman D. J. Oxidative metabolism of cyclophosphamide. Identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res. 1988; 49: 2344–2350
  • Cox P. J., Farmer P. B., Jarman M., Kinas R. W., Stec W. J. Stereoselectivity in the metabolism of the enantiomers of cyclophosphamide in mice, rats, and rabbits. Drug Metab. Dispos. 1978; 6: 617–622
  • Farmer P. B. Enantiomers of cyclophosphamide and iphospha-mide. Biochem. Pharmacol. 1988; 37: 145–148
  • Martz G., D'Alessandri A., Keel H. J., Bollag W. Preliminary clinical results with a new antitumor agent RO 4–6467 (NSC-77213). Cancer Chemother. Rep. 1963; 33: 5–15
  • Spivack S. D. Procarbazine. Ann. Int. Med. 1974; 81: 795–800
  • Baggiolini M., Dewald B., Aebi H. Oxidation of p-(N1-methylhydrazino methyl)-7V-isopropyl benzamide (procarbazine) to the methylazo derivative and oxidative cleavage of the N2–C bond in the isolated perfused rat liver. Biochem. Pharmacol. 1969; 18: 2187–2196
  • Oliverio V. T., Denham Ch., DeVita V. T., Kelly M. G. Some pharmacologic properties of a new antitumor agent, N-iso-propyl-alpha-(2-methylhydrazino)-p-toluamide, hydrochloride (NSC-77213). Cancer Chemother. Rep. 1964; 42: 1–7
  • Prough R. A., Wittkop J. A., Reed D. J. Further evidence on the nature of microsomal metabolism of procarbazine and related alkylhydrazines. Arch. Biochem. Biophys. 1970; 140: 450–458
  • Weinkam R. J., Shiba D. A. Metabolic activation of procarbazine. Life Sci. 1978; 22: 937–946
  • Dunn D. L., Lubet R. A., Prough R. A. Oxidative metabolism of Ar-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride (procarbazine) by rat liver microsomes. Cancer Res. 1979; 39: 4555–4563
  • Wiebkin P., Prough R. A. Oxidative metabolism of N-iso-propyl-alpha-(2-methylazo)-p-toluamide (azoprocarbazine) by rodent liver microsomes. Cancer Res. 1980; 40: 3524–3529
  • Prough R. A., Brown M. I., Dannan G. A., Guengerich F. P. Major isozymes of rat liver microsomal cytochrome P-450 involved in the N-oxidation of N-isopropyl-alpha-(2-methylazo)-p-toluamide, the azo derivative of procarbazine. Cancer Res. 1984; 44: 543–548
  • Prough R. A., Tweedie D. J. Procarbazine. Metabolism and Action of Anticancer Drugs, G. Powis, R. A. Prough. Taylor & Francis, New York 1987; 29–47
  • Moloney S. J., Wiebkin P., Cummings S. W., Prough R. A. Metabolic activation of the terminal Af-methyl group of AMso-propyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride (procarbazine). Carcinogenesis 1985; 6: 397–401
  • Rozencweig M., Von Hoff D. D., Henney J. E., Muggia F. M. VM 26 and VP 16–213: A comparative analysis. Cancer 1977; 40: 334–342
  • O'Dwyer P. J., Leyland-Jones B., Alonso M. T., Marsoni S., Wittes R. E. Etoposide (VP-16–213). Current status of an active anticancer drug. N. Engl. J. Med. 1985; 312: 692–700
  • Issell B. F., Rudolph A. R., Lorrie A. C. Etoposide (VP-16), Current Status and New Developments, B. F. Issell, F. M. Muggia, S. K. Carter. Academic Press, Orlando, FL 1984; 6–8
  • Loike J. D., Horwitz S. B. Effect of VP-16–213 on the intracellular degradation of DNA in HeLa cells. Biochemistry 1976; 15: 5443–5449
  • Chen G. L., Yang L., Rowe T. C, Halligan B. D., Tewey K. M., Liu L. F. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoiso-merase II. J Biol. Chem. 1984; 259: 13560–13566
  • Wozniak A. J., Glisson B. S., Hande K. R., Ross W. E. Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents. Cancer Res. 1984; 44: 626–632
  • Evans W. E., Sinkule J. A., Crom W. R., Dow L., Look A. T., Rivera G. Phamacokinetics of teniposide (VM26) and etoposide (VP16–213) in children with cancer. Cancer Chemother. Pharmacol. 1982; 7: 147–150
  • Colombo T., D'lncalci M., Donelli M. G., Bartock I., Benfenati E., Farina P., Guartani A. Metabolic studies of a podophyllotoxin derivative (VP16) in the isolated perfused liver. Xenobiotica 1985; 15: 343–350
  • Haim N., Nemec J., Roman J., Sinha B. K. In vitro metabolism of etoposide (VP-16–213) by liver microsomes and irreversible binding of reactive intermediates to microsomal proteins. Biochem. Pharmacol. 1987; 36: 527–536
  • Van Maanen J. M. S., de Vries J., Pappie D., van den Akker E., Lafleur M. V. M., Retel J., van der Greef J., Pinedo H. M. Cytochrome P-450-mediated O-demethylation: A route in the metabolic activation of etoposide (VP-16–213). Cancer Res. 1987; 47: 4658–4662
  • Van Maanen J. M. S., de Ruiter C, Kootstra P. R., Lafleur M. V. M., de Vries J., Retel J., Pinedo H. M. Inactivation of Phi Z174 DNA by the orthoquinone derivative or its reduction product of the antitumor agent VP16–213. Eur. J. Cancer Clin. Oncol. 1985; 21: 1215–1218
  • Long B. H., Musial S. T., Brattain M. G. Comparison of cytotoxicity and DNA breakage activity of congeners of Podophyllotoxin including VP16–213 and VM26: a quantitative structure-activity relationship. Biochemistry 1984; 23: 1183–1188
  • Sinha B. K., Myers C. E. Irreversible binding of etoposide (VP-16–213) to deoxyribonucleic acid and proteins. Biochem. Pharmacol. 1984; 33: 3725–3734
  • Sinha B. K., Eliot H. M., Kalayanaraman B. Iron-dependent hydroxyl radical formation and DNA damage from a novel metabolite of the clinically active antitumor drug VP-16. FEBS Lett. 1988; 227: 240–244
  • Gupta R. S. Genetic, biochemical and cross-resistant studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-16 and VP16–213. Cancer Res. 1983; 43: 1568–1574
  • Teicher B. A., Holden S. A., Rose C. M. Effect of oxygen on the cytotoxicity and antitumor activity of etoposide. J. Natl. Cancer Inst. 1985; 75: 1129–1134
  • Schein P. S. Nitrosoureas. Cancer and Chemotherapy, S. T. Crooke, A. W. Prestayko, N. Alder. Academic Press, New York 1981; 37–47
  • Ali-Osmar F., Giblin J., Berger M., Murphy M. J., Jr., Rosenblum M. L. Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosoureas. Cancer Res. 1985; 45: 4185–4191
  • Reed D. J. Metabolism of nitrosoureas. Nitrosoureas, A. W. Prestayko, L. H. Baker, S. T. Crooke, S. K. Carter, P. S. Schein. Academic Press, New York 1981; 51–66
  • Reed D J. 2-Chloroethylnitrosoureas. Metabolism and Action of Anticancer Drugs, G. Powis, R. A. Prough. Taylor & Francis, New York 1987; 1–28
  • May H. E., Boose R., Reed D. J. Hydroxylation of the carcinostatic 1 -(2-chloroethyl)-3-cyclohexyl-1 -nitrosourea (CCNU) by rat liver microsomes. Biochem. Biophys. Res. Com-mun. 1974; 57: 426–433
  • Hill D. L., Kirk M. C, Struck R. F. Microsomal metabolism of nitrosoureas. Cancer Res. 1975; 35: 296–301
  • Yeowell H. N., Waxman D. J., Wadhera A., Goldstein J. A. Suppression of the constitutive, male-specific rat hepatic cytochrome P-450 2c and its mRNA by 3,4,5,3 ',4 ',5 '-hexachlorobi-phenyl and 3-methylcholanthrene. Mol. Pharmacol. 1987; 32: 340–347
  • Potter D. W., Levin W., Ryan D. E., Thomas P. E., Reed D. J. Stereoselective monooxygenation of carcinostatic l-(2-chloroethyl)-3-(cyclohexyl)-l-nitrosourea and l-(2-chloroethyl)-3-(f/wts-4-meth-ylcyclohexyl)-l-nitrosourea by purified cytochrome P-450 isozymes. Biochem. Pharmacol. 1984; 33: 609–613
  • May H. E., Kohlhepp S. J., Boose R. B., Reed D. J. Synthesis and identification of products derived from the metabolism of the carcinostatic l-(2-cnloroethyi)-3-(fraHS-4-methylcyclohex-yl)-l-nitrosourea by rat liver microsomes. Cancer Res. 1979; 39: 762–772
  • Levin V. A., Stearns J., Byrd A., Finn A., Weinkam R. J. The effect of phenobarbital pretreatment on the antitumor activity of l,3-bis(2-chloroethyl)-l-nitrosourea (BCNU), l-(2-chloro-ethyl)-3-cyclohexyl-l-nitrosourea (CCNU) and l-(2-chloroethyl)-3-(2,6-dioxo)-3-piperidyl-l-nitrosourea (PCNU), and on the plasma pharmacokinetics…. J. Pharmacol. Exp. Ther. 1979; 208: 1–6
  • Potter D. W., Reed D. J. Involvement of FMN and phenobarbital cytochrome P-450 in stimulating a one-electron reductive denitrosation of l-(2-chloroethyl)-3-(cyclohexyl)-l-ni-trosurea catalyzed by NADPH-cytochrome P-450 reductase. J. Biol. Chem. 1983; 258: 6906–6911
  • Potter D. W., Reed D. J. Denitrosation of carcinostatic nitrosoureas by purified NADPH cytochrome P-450 reductase and rat liver microsomes to yield nitric oxide under anaerobic conditions. Arch. Biochem. Biophys. 1982; 216: 158–169
  • High-dose thiotepa and autologous marrow transplantation. Advances in Cancer Chemotherapy, G. P. Herzig. Park Row Publishers. 1987; 1–53
  • Cohen B. E., Egorin M. J., Kohlhepp E. A., Aisner J., Gutierrez P. L. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites. Cancer Treat. Rep. 1986; 70: 859–864
  • Egorin M. J., Akman S. R., Gutierrez P. L. Plasma pharmacokinetics and tissue distribution of thiotepa in mice. Cancer Treat. Rep. 1984; 68: 1265–1268
  • Breau A. P., Field L., Mitchell W. M. Thiono compounds. 4. In vitro mutagenic and antineoplastic activity of tepa and thio-tepa. Cell. Biol. Toxicol. 1984; 1: 21–30
  • Kamataki T., Belcher D. H., Neal R. A. Studies on the metabolism of diethyl p-nitrophenyl-phosphorothionate (parathion) and benzphetamine using an apparently homogeneous preparation of rat liver cytochrome P-450: effect of a cytochrome P-450 antibody preparation. Mol. Pharmacol. 1976; 12: 921–932
  • Teicher B. A., Holden S. A., Cucchi C. A., Cathcart K. N. S., Korbut T. T., Flatow J. L., Frei E., III. Combinations of N,W,W″-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. Cancer Res. 1988; 48: 94–100
  • Berrigan M. J., Marinello A. J., Pavelic Z., Williams C. J., Struck R. F., Gurtoo H. L. Protective role of thiols in cyclophosphamide-induced urotoxicity and depression of hepatic drug metabolism. Cancer Res. 1982; 42: 3688–3695
  • Donelli M. G., Franchi G., Rosso R. The effect of cytotoxic agents on drug metabolism. Eur. J. Cancer 1970; 6: 125–126
  • Donelli M. G., Bartosek I., Guaitani A., Martini A., Colombo T., Pacciarini M. A., Modica R. Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect. Cancer Treat. Rep. 1976; 60: 395–401
  • Sladek N. E., Priest J., Doeden D., Mirocha C. J., Pathre S., Krivit W. Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat. Rep. 1980; 64: 1061–1066
  • Satoh K. Purification, induction, and distribution of placental glutathione transferase: A new marker enzyme for preneoplastic cells in the rat chemical hepatocarcinogenesis. Proc. Natl. Acad. Sci. USA 1985; 82: 3964–3968
  • Tsuda H., Moore M. A., Asamoto M., Inoue T., Fukushima S., Ito N., Satoh K., Amelizad Z., Oesch F. Immuno-histochemically demonstrated altered expression of cytochrome P-450 molecular forms and epoxide hydrolase in N-ethyl-N-hydroxyethylnitrosamine-induced rat kidney and liver lesions. Carcinogenesis 1987; 8: 711–717
  • Marinello A. J., Gurtoo H. L., Struck R. F., Paul B. Denaturation of cytochrome P-450 by cyclophosphamide metabolites. Biochem. Biophys. Res. Commun. 1978; 83: 1347–1353
  • Marinello A. J., Bansal S. K., Paul B., Koser P. L., Love J., Struck R. F., Gurtoo H. L. Metabolism and binding of cyclophosphamide and its metabolite acrolein to rat hepatic microsomal cytochrome P-450. Cancer Res. 1984; 44: 4615–4621
  • LeBlanc G., Waxman D. J. Differential modulation of rat hepatic cytochrome P-450 enzymes upon exposure to cisplatin and cyclophosphamide. Proc. Am. Assoc. Cancer Res. 1987; 28: 314
  • Murphy S. D. Mechanism of the effect of acrolein on rat liver enzymes. Toxicol. Appl. Pharmacol. 1965; 7: 833–843
  • Ozols R. F., Young R. C. High dose cisplatin therapy in ovarian cancer. Sem. Oncol. 1985; 12: 21–30
  • Borch R. F. The platinum anti-tumour drugs. Metabolism and Action of Anticancer Drugs, G. Powis, R. A. Prough. Taylor & Francis, New York 1987; 163–193
  • Pinto A. L., Lippard S. J. Binding of the antitumor drug cJs-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochem. Biophys. Acta 1985; 780: 167–180
  • Litterst C. L., Tong S., Hirokata Y., Siddik Z. H. Stimulation of microsomal drug oxidation in liver and kidney of rats treated with the oncolytic agent os-dichlorodiammineplati-num-II. Pharmacology 1983; 46–53
  • Jollie D. R., Maines M. D. Effect of cis-platinum on kidney cytochrome P-450 and heme metabolism: Evidence for the regulatory role of the pituitary hormones. Arch. Biochem. Biophys. 1985; 240: 51–59
  • Maines M. D. Differential effect of m-platinum (c/s-diammine-dichloroplatinum) on regulation of liver and kidney haem and haemoprotein metabolism. Biochem. J. 1986; 237: 713–721
  • Maines M. D., Mayer R. D. Inhibition of testicular cytochrome P-450-dependent steroid biosynthesis by cis-platinum. J. Biol. Chem. 1985; 260: 6063–6068
  • Waterman M. R., John M. E., Simpson E. R. Regulation of synthesis and activity of cytochrome P-450 enzymes in physiological pathways. Cytochrome P-450: Structure, Mechanism, and Biochemistry, P. R Ortiz de Montellano. Pergamon Press. 1986; 345–386
  • LeBlanc G. A., Waxman D. J. Feminization of rat hepatic P-450 expression by cisplatin. Evidence for perturbations in the hormonal regulation of steroid-metabolizing enzymes. J. Biol. Chem. 1988; 263: 15732–15739
  • Eiseman J. L., Bernstein A. L., Ferraro T. A. Effects of platinum anticancer agents on murine heme biosynthesis and drug metabolism. Pharmacologist 1985; 27: 152
  • Donelli M. G., Garattini S. Drug metabolism after repeated treatments with cytotoxic agents. Eur. J. Cancer 1971; 7: 361–364
  • Gooderham N. J., Mannering G. J. Depression of the hepatic cytochrome P-450 monooxygenase system by treatment of mice with the antineoplastic agent 5-azacytidine. Cancer Res. 1985; 45: 1569–1572
  • Reed D. J., May H. E. Cytochrome P-450 interactions with the 2-chloroethylnitrosoureas and procarbazine. Biochimie 1978; 60: 989–995
  • Litterst C. L. Prolonged depression of hepatic microsomal drug metabolism and hemoprotein levels following a single dose of l-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU). Biochem. Pharmacol. 1981; 30: 1014–1016
  • Buchmann A., Kuhlmann W., Schwarz M., Kunz W., Wolf C. R., Moll E., Friedberg T., Oesch F. Regulation and expression of four cytochrome P-450 isoenzymes, NADPH-cyto-chrome P-450 reductase, the glutathione transferases B and C and microsomal epoxide hydrolase in preneoplastic and neoplastic lesions in rat liver. Carcinogenesis 1985; 6: 513–521
  • Schwarz M., Peres G., Buchmann A., Friedberg T., Waxman D. J., Kunz W. Phenobarbital induction of cytochrome P-450 in normal and preneoplastic rat liver: comparison of enzyme and mRNA expression as detected by immuno histochemistry and in situ hybridization. Carcinogenesis 1987; 8: 1355–1357
  • Giron C. G., Ordonez A., Jalon J. I., Baron M. G. Combination chemotherapy with ifosfamide, mitomycin, and cis-platin in advanced non-small cell lung cancer. Cancer Treat. Rep. 1987; 71: 851–853
  • Reed E., Litterst C. L., Thill C. C, Yuspa S. H., Poirier M. C. m-Diamminedichloroplatinum(II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats. Cancer Res. 1987; 47: 718–722
  • Guarino A. M., Miller D. S., Arnold S. T., Pritchard J. B., Davis R. D., Urbanek M. A., Miller T. J., Litterst C. L. Platinate toxicity: past, present and prospects. Cancer Treat. Rep. 1979; 63: 1475–1483
  • Song B-J., Gelboin H. V., Park S. S., Tsokos G. C, Friedman F. K. Monoclonal antibody-directed radioimmunoassay detects cytochrome P-450 in human placenta and lymphocytes. Science 1985; 228: 490–492
  • Waxman D. J. Rat hepatic cytochrome P-450 isoenzyme 2c. Identification as a male-specific, developmental induced steroid 16alpha-hydroxylase and comparison to a female-specific cytochrome P-450 isoenzyme. J. Biol. Chem. 1984; 259: 15481–15490
  • Guengerich F. P., Dannan G. A., Wright S. T., Martin M. V., Kaminsky L. S. Purification and characterization of liver microsomal cytochromes P-450: electrophoretic, spectral, catalytic and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone. Biochemistry 1982; 21: 6019–6030
  • Waxman D. J., Dannan G. A., Guengerich F. P. Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry 1985; 24: 4409–4417
  • Sladek N. E., Doeden D., Powers J. F., Krivit W. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat. Rep. 1984; 68: 1247–1254
  • Allen L. M., Creaven P. J., Nelson R. L. Studies on the human pharmacokinetics of isophosphamide (NSC-109724). Cancer Treat. Rep. 1976; 60: 451–458
  • Colvin M. The comparative pharmacology of cyclophosphamide and ifosphamide. Sent. Oncol. 1982; 9: 2–7
  • Gut J., Catin T., Dayer P., Kronbach T., Zanger U., Meyer U. A. Debrisoquine/sparteine-type polymorphism of drug oxidation: purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J. Biol. Chem. 1986; 261: 11734–11743
  • Guengerich F. P., Martin M. V., Beaune P. H., Kremers P., Wolff T., Waxman D. J. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol. Chem. 1986; 261: 5051–5060
  • Wrighton S. A., Campanile C, Thomas P. E., Maines S. L., Watkins P. B., Parker G., Mendez-Picon G., Haniu M., Shiveley J. E., Levin W., Guzelian P. S. Identification of a human liver cytochrome P-450 homologous to the major iso-safrole-inducible cytochrome P-450 in the rat. Mol. Pharmacol. 1986; 29: 405–410
  • Waxman D. J., Clarke L., Ng S. Oxidative metabolism of thio-TEPA: Role of hepatic cytochrome P-450. Proc. Am. Assoc. Cancer Res. 1989; 30: 463
  • Teicher B. A., Waxman D. J., Holden S. A., Wang Y., Clarke L., Alvarez E., Jones S. M., Frei E, Ill. N,N′,N″-Triethylenethiophosphoramide: Evidence for an enzymatic and oxygen involvement in activation. Cancer Res. 1989, submitted for publication
  • Aoyama T., Yamano S., Waxman D. J., Lapenson D. P., Meyer U. A., Fischer V., Tyndale R., Inaba T., Kalow W., Gelboin H. V., Gonzalez F. J. Cytochrome P450 hPCN3, a novel P450IIIA gene product that is differentially expressed in adult human liver: cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCNl and hPCN3 for the metabolism of steroid hormones and cyclosporine. J. Biol. Chem. 1989, in press

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.